Ge R - Search Results

1

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.

Xu X, Ge R, Li L, Wang J, Lu X, Xue S, Chen X, Li Z, Bian J. Xu X, et al. Among authors: ge r. Eur J Med Chem. 2018 Jan 1;143:1325-1344. doi: 10.1016/j.ejmech.2017.10.031. Epub 2017 Oct 14. Eur J Med Chem. 2018. PMID: 29117897

2

Progress in the mechanism and drug development of castration-resistant prostate cancer.

Zuo M, Xu X, Li T, Ge R, Li Z. Zuo M, et al. Among authors: ge r. Future Med Chem. 2016 May;8(7):765-88. doi: 10.4155/fmc.16.12. Epub 2016 May 5. Future Med Chem. 2016. PMID: 27149562 Review.

3

Synthesis and biological evaluation of 6-fluoro-3-phenyl-7-piperazinyl quinolone derivatives as potential topoisomerase I inhibitors.

Ge R, Zhao Q, Xie Z, Lu L, Guo Q, Li Z, Zhao L. Ge R, et al. Eur J Med Chem. 2016 Oct 21;122:465-474. doi: 10.1016/j.ejmech.2016.06.054. Epub 2016 Jul 1. Eur J Med Chem. 2016. PMID: 27416553

4

Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.

Zuo M, Xu X, Xie Z, Ge R, Zhang Z, Li Z, Bian J. Zuo M, et al. Among authors: ge r. Eur J Med Chem. 2017 Jan 5;125:1002-1022. doi: 10.1016/j.ejmech.2016.10.049. Epub 2016 Oct 22. Eur J Med Chem. 2017. PMID: 27810589

5

Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro.

Wang J, Ge R, Qiu X, Xu X, Wei L, Li Z, Bian J. Wang J, et al. Among authors: ge r. Eur J Med Chem. 2017 Nov 10;140:421-434. doi: 10.1016/j.ejmech.2017.09.046. Epub 2017 Sep 22. Eur J Med Chem. 2017. PMID: 28987604

6

Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.

Ge R, Xu X, Xu P, Li L, Li Z, Bian J. Ge R, et al. Curr Cancer Drug Targets. 2018;18(7):652-667. doi: 10.2174/1568009617666171107103936. Curr Cancer Drug Targets. 2018. PMID: 29110617 Review.

7

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.

Xu P, Shen P, Yu B, Xu X, Ge R, Cheng X, Chen Q, Bian J, Li Z, Wang J. Xu P, et al. Among authors: ge r. Eur J Med Chem. 2020 Apr 15;192:112155. doi: 10.1016/j.ejmech.2020.112155. Epub 2020 Feb 18. Eur J Med Chem. 2020. PMID: 32120325 Review.

8

Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.

Xu X, Du Q, Meng Y, Li Z, Wu H, Li Y, Zhao Z, Ge R, Lu X, Xue S, Chen X, Yang Y, Wang J, Bian J. Xu X, et al. Among authors: ge r. Eur J Med Chem. 2020 Apr 15;192:112196. doi: 10.1016/j.ejmech.2020.112196. Epub 2020 Mar 5. Eur J Med Chem. 2020. PMID: 32169785

9

Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2.

Xu P, Shen P, Wang H, Qin L, Ren J, Sun Q, Ge R, Bian J, Zhong Y, Li Z, Wang J, Qiu Z. Xu P, et al. Among authors: ge r. Eur J Med Chem. 2021 Jun 5;218:113394. doi: 10.1016/j.ejmech.2021.113394. Epub 2021 Mar 26. Eur J Med Chem. 2021. PMID: 33813153

10

Current knowledge on the nucleotide agonists for the P2Y2 receptor.

Xu P, Feng X, Luan H, Wang J, Ge R, Li Z, Bian J. Xu P, et al. Among authors: ge r. Bioorg Med Chem. 2018 Jan 15;26(2):366-375. doi: 10.1016/j.bmc.2017.11.043. Epub 2017 Dec 2. Bioorg Med Chem. 2018. PMID: 29254895 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,677 results

Search Page

Filters